GondolaBio, LLC

GondolaBio, LLC is a collection of biopharmaceutical companies focused on developing next-generation therapeutics for genetic diseases. Originally carved out of BridgeBio, GondolaBio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients suffering from genetic diseases. The lead program in GondolaBio’s portfolio is Portal Therapeutics, which is developing a novel potential best-in-class therapy for erythropoietic protoporphyria, a severe genetic disease.